Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.52 |
| ▸ | AKT1 | P31749 | 12/20 | 0.49 |
| ▸ | AKT2 | P31751 | 4/20 | 0.49 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.40 |
| ▸ | AKT1S1 | Q96B36 | 4/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473313 | 0.88 | AKT1 (0.41) | RPS6KB1AKT1AKT2AKT3RPS6KA3 | |
| SCHEMBL10159398 | 0.88 | AKT1 (0.49) | RPS6KB1AKT1AKT2AKT3TSHR | |
| SCHEMBL23532317 | 0.85 | AKT1 (0.54) | RPS6KB1AKT1AKT2AKT3ROCK2 | |
| SCHEMBL473355 | 0.81 | AKT1 (0.43) | RPS6KB1AKT1AKT2AKT3RPS6KA3 | |
| SCHEMBL23532315 | 0.80 | AKT1S1 (0.59) | RPS6KB1AKT1AKT2AKT3AKT1S1 | |
| SCHEMBL473320 | 0.80 | AKT1 (0.42) | RPS6KB1AKT1AKT2RPS6KA3 | |
| SCHEMBL473314 | 0.78 | AKT1 (0.40) | RPS6KB1AKT1AKT2AKT3RPS6KA3 | |
| SCHEMBL25083520 | 0.77 | RPS6KB1 (0.55) | RPS6KB1AKT1AKT2AKT3RPS6KA3 | |
| SCHEMBL14782328 | 0.74 | RPS6KB1 (0.76) | RPS6KB1 | |
| SCHEMBL473379 | 0.74 | RPS6KB1 (0.53) | RPS6KB1AKT1AKT2AKT3RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230064189-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-03-02 | — | — | US | claimed |
| EP-4077329-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | Imperial College Innovations Limited (GB) | 2022-10-26 | — | — | EP | claimed |
| WO-2021123798-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2021-06-24 | — | — | WO | claimed |
| EP-1848719-B1 | [1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-YL]-PIPERIDINE OR -PIPERAZINE COMPOUNDS AS SERINE-THREONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES | EXELIXIS INC (US) | 2012-02-01 | — | — | EP | claimed |
| US-7994172-B2 | [1-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methanol; kinase-dependent diseases, invasive cell growth, and metabolism | EXELIXIS, INC. (US) | 2011-08-09 | — | — | US | claimed |
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | EXELIXIS, INC. (US) | 2008-08-07 | — | — | US | claimed |
| US-20230064189-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-03-02 | — | — | US | disclosed |
| US-20230064189-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-03-02 | — | — | US | disclosed |
| EP-4077329-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | Imperial College Innovations Limited (GB) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021123798-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2021-06-24 | — | — | WO | disclosed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| EP-2139484-B9 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2139483-B9 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | EXELIXIS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | EXELIXIS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | EXELIXIS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | EXELIXIS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
| EP-1848719-A1 | [1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-YL]-PIPERIDINE OR -PIPERAZINE COMPOUNDS AS SERINE-THREONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006071819-A1 | [1H-PYRAZOLO[3, 4-D]PYRIMIDIN-4-YL]-PIPERIDINE OR -PIPERAZINE COMPOUNDS AS SERINE-THEORONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230064189-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | DPYD, ABCC1, TYMP | RPS6KB1 1491/4885AKT1 2327/4885AKT2 2208/4885 |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | TP53, PHKG1, TNNI3K | RPS6KB1 444/4885AKT1 153/4885AKT2 343/4885 |
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | PDPK1, MTOR, RPS6KA2 | RPS6KB1 10/4885AKT1 14/4885AKT2 6/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | RPS6KB1 700/4885AKT1 97/4885AKT2 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.